Key Highlights
- Third-quarter 2026 collaboration Revenue was USD 15.3 million, against USD 12.3 million a year earlier.
- Net loss was USD 4.3 million, against USD 37 thousand in the prior-year quarter.
- Research and development expenses were USD 13.8 million, up from USD 9.7 million.
- Short-term investments were USD 187.5 million and cash equivalents were USD 44.6 million.
Atrium Therapeutics (NASDAQ:RNA) reported third-quarter 2026 collaboration revenue of USD 15.3 million, against an estimate of USD 15.00 million, in its Quarterly Report on Form 10-Q. The net loss was USD 0.25 per share, against an estimate of a loss of USD 0.81. The company develops targeted therapies for cardiac conditions and was separated from Avidity Biosciences in a spin-off completed in early 2026.
Revenue and Expenses
Collaboration revenue was USD 15.3 million for the three months ended September 30, 2026, against USD 12.3 million a year earlier, an increase of USD 3.0 million. The filing attributes the increase to USD 5.0 million of higher milestone revenue, driven by a USD 15.0 million milestone under the BMS Collaboration Agreement against a USD 10.0 million milestone under the Lilly Agreement in the prior-year period, partly offset by USD 2.0 million less service-related Research and Development revenue. For the nine months, collaboration revenue was USD 38.0 million, against USD 17.8 million.
Research and development expenses were USD 13.8 million, against USD 9.7 million. External costs were USD 7.2 million, including USD 3.1 million for ATR 1086 and USD 2.0 million for ATR 1072. The company states higher ATR 1086 costs reflect Manufacturing and IND-enabling nonclinical work, partly offset by lower ATR 1072 costs as that program moved from IND-enabling work to clinical site initiation. Internal costs were USD 6.6 million, against USD 4.0 million.
General and administrative expenses were USD 8.2 million, against USD 2.8 million. Total operating expenses were USD 22.0 million, against USD 12.6 million. Total other income was USD 2.4 million, and the net loss was USD 4.3 million, against USD 37 thousand a year earlier. For the nine months, the net loss was USD 41.1 million, against USD 20.4 million.
Pipeline Progress
The company said the U.S. Food and Drug Administration cleared its Investigational New Drug application for ATR 1072, allowing the Corventis Phase 1/2 clinical trial for the treatment of PRKAG2 syndrome to move forward, and that Health Canada issued a No Objection Letter enabling activation of planned study sites in Canada. In October 2026, the company announced it dosed the first patient in the trial. It states initial trial data demonstrating proof of concept are anticipated in the second half of 2027.
Its second lead candidate, ATR 1086, is a siRNA-based therapy targeting phospholamban for the treatment of PLN cardiomyopathy. The company states nonclinical studies to date have demonstrated its potency and selectivity for PLN silencing, and projects it plans to file an IND for ATR 1086 in 2027.
Balance Sheet and Spin-Off Background
At September 30, 2026, cash and cash equivalents were USD 44.6 million and short-term investments were USD 187.5 million, against no cash or short-term investments at December 31, 2025. Total Assets were USD 264.0 million. A collaboration receivable of USD 15.0 million was outstanding. Net cash provided by financing activities for the nine months was USD 295.2 million, including USD 301.5 million of net transfers from the former parent.
The company states it believes existing cash, cash equivalents and short-term investments are sufficient to fund operations for at least 12 months from the filing date of the quarterly report.
In the spin-off, 15,514,966 shares of common stock were distributed to holders of the former parent's common stock on the basis of one share for every 10 shares held as of the close of Business on February 12, 2026. The company's common stock trades on the Nasdaq Global Select Market. It also adopted a 2026 Employment Inducement Incentive Award Plan in April 2026 and a 2026 Employee Stock Purchase Plan, effective in February 2026.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...